Other grades of this product :
| Velpatasvir Basic information |
| Product Name: | Velpatasvir | | Synonyms: | Velpatasvir;GS 5816;velpatasvir(GS-5816);methyl ((2s)-1-((2s,5s)-2-(9-(2-((2s,4s)-1-((2r)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1h-imidazol-5-yl)-1,11-dihydroisochromeno(4',3':6,7)naphtho(1,2-d)imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate;Velpatasvir API;Unifiram (DM-232);GS 5816;GS-5816;CS-2204 | | CAS: | 1377049-84-7 | | MF: | C49H54N8O8 | | MW: | 883 | | EINECS: | 1592732-453-0 | | Product Categories: | 1377049-84-7 | | Mol File: | 1377049-84-7.mol |
| Velpatasvir Chemical Properties |
| Melting point | >170oC (dec.) | | density | 1.314±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (>25 mg/ml) | | form | solid | | pka | 10.75±0.46(Predicted) | | color | Pale yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Velpatasvir Usage And Synthesis |
| Description | Velpatasvir (1377049-84-7) is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa? and Vosevi?, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV.? It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.2 | | Uses | Velpatasvir is a NS5A inhibitor in patients with hepatitis C (HCV) infection. | | Definition | ChEBI: A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes. | | References | Link et al. (2019), Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi? and Epclusa?; Bioorg. Med. Chem. Lett., 29 2415
Kadioglu et al. (2020), Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning; Comput. Biol. Med. 133 104359 |
| Velpatasvir Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye